Article info
PDFNeuromuscular
Research paper
Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study
- Correspondence to Professor Ryuji Kaji, Department of Neurology, Tokushima University School of Medicine, Tokushima 770-8503, Japan; rkaji{at}tokushima-u.ac.jp
Citation
Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study
Publication history
- Received July 24, 2018
- Revised November 20, 2018
- Accepted November 27, 2018
- First published January 13, 2019.
Online issue publication
July 18, 2023
Article Versions
- Previous version (31 May 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.